Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?

医学 胃肠病学 内科学
作者
Marlyn J. Mayo
出处
期刊:Hepatology [Wiley]
卷期号:76 (2): 518-531 被引量:27
标识
DOI:10.1002/hep.32405
摘要

Abstract Treatment of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to prevent progression to hepatic decompensation and/or need for liver transplant. Adjuvant therapy with obeticholic acid may provide additional biochemical improvements in some patients, but it is not well‐tolerated by patients with significant itch or advanced cirrhosis. Thus, new and creative approaches to treating patients with PBC are important to identify. This review discusses major potential therapeutic targets in PBC and provides examples of some specific agents currently in development for the treatment of PBC. Targets are broadly classified into those which strive to modify bile, inflammation, cell survival, or fibrosis. In bile, shrinking the size of the bile acid pool or modifying the quality of the bile by making it more hydrophilic or enriched in phosphatidylcholine may ameliorate cholestatic injury. Biliary epithelial cell survival may be extended by fortifying the bicarbonate umbrella or improving cell membrane integrity. Autoimmunity and cholangitis have the potential to be improved via regulation of the immune system. Targeting cytokines, immune checkpoints, and anti‐mitochondrial antibodies are examples of a more focused immunosuppression approach. Stem cell therapy and lymphocyte trafficking inhibition are more novel methods of broad immune regulation. Anti‐fibrotic therapies are also potentially useful for preventing progression of PBC. The nuclear hormone receptors, farnesoid X receptor (FXR) and peroxisome proliferator–activated receptor (PPAR) regulate many of these pathways: cholestasis, inflammation, and fibrosis, which is why they are being enthusiastically pursued as potential therapeutic targets in PBC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
大模型应助高大的曼寒采纳,获得10
1秒前
汉堡包应助jwb711采纳,获得20
1秒前
1秒前
Owen应助wen采纳,获得10
1秒前
SciGPT应助是十二呀采纳,获得10
2秒前
天才小熊猫完成签到,获得积分10
2秒前
科研通AI2S应助立冬采纳,获得10
2秒前
jiexika完成签到,获得积分10
2秒前
3秒前
3秒前
楼北完成签到,获得积分10
3秒前
柠木完成签到 ,获得积分10
3秒前
鱼腩发布了新的文献求助10
4秒前
坦率的棉花糖完成签到 ,获得积分10
4秒前
sfxnxgu发布了新的文献求助10
4秒前
含蓄元冬发布了新的文献求助10
5秒前
淋漓尽致发布了新的文献求助10
5秒前
hsy完成签到,获得积分10
6秒前
尊敬乐蕊发布了新的文献求助20
6秒前
7秒前
7秒前
HelloJoey发布了新的文献求助10
10秒前
淋漓尽致完成签到,获得积分10
10秒前
都是发布了新的文献求助10
10秒前
佳敏完成签到,获得积分10
11秒前
鱼腩完成签到,获得积分10
11秒前
科研通AI2S应助xiaozhu采纳,获得10
11秒前
嗝嗝发布了新的文献求助10
11秒前
12秒前
junjun发布了新的文献求助10
12秒前
星辰大海应助时尚问安采纳,获得10
12秒前
科研小白董完成签到 ,获得积分10
13秒前
15秒前
18秒前
18秒前
18秒前
21秒前
21秒前
zhang完成签到,获得积分20
22秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139146
求助须知:如何正确求助?哪些是违规求助? 2790083
关于积分的说明 7793577
捐赠科研通 2446452
什么是DOI,文献DOI怎么找? 1301175
科研通“疑难数据库(出版商)”最低求助积分说明 626106
版权声明 601102